Concepedia

Author

Bo Åhrén

Lund UniversityORCID

Also Known As

AHREN, B, Ahren B, Ahren, B, Ahren, Bo, Ahrén, Bo, B AHREN, B Ahren, B Ahrén, B Ahrén, B O AHREN

879

Publications

41.1K

Citations

102

H-Index

224

Concepts

All Affiliations

Lund UniversityMalmö UniversityKarolinska Institutet
BÅ

About

Bo Åhrén is an author at Lund University specializing in medicine, diabetes, and physiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

60

240

14.3K

2

Health Sciences

40

107

8K

3

Natural Sciences

11

11

353

4

Education

2

2

211

5

Engineering

1

1

10

Bo Åhrén

×

467

Publications

31.8K

Citations

90

H-Index

YearCitations

Interleukin-6-deficient mice develop mature-onset obesity

Ville Wallenius, Kristina Wallenius, Bo Åhrén,

Nature Medicine

2002

1.2K

The High-Fat Diet–Fed Mouse

Maria Sörhede Winzell, Bo Åhrén

Diabetes

2004

1K

Antidiabetogenic Effect of Glucagon-like Peptide-1 (7–36)amide in Normal Subjects and Patients with Diabetes Mellitus

M. Gutniak, Cathrine Ørskov, Jens J. Holst,

New England Journal of Medicine

1992

868

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Bo Åhrén, Mona Landin‐Olsson, Per‐Anders Jansson,

The Journal of Clinical Endocrinology & Metabolism

2004

711

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease

Thomas Nyström, M. Gutniak, Qimin Zhang,

American Journal of Physiology-Endocrinology and Metabolism

2004

667

FOXC2 Is a Winged Helix Gene that Counteracts Obesity, Hypertriglyceridemia, and Diet-Induced Insulin Resistance

Anna Cederberg, Line M. Grønning, Bo Åhrén,

Cell

2001

556

Twelve- and 52-Week Efficacy of the Dipeptidyl Peptidase IV Inhibitor LAF237 in Metformin-Treated Patients With Type 2 Diabetes

Bo Åhrén, Ramón Gomis, Eberhard Standl,

Diabetes Care

2004

485

Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial

Bo Åhrén, Luís Masmiquel, Harish Kumar,

The Lancet Diabetes & Endocrinology

2017

445

Inhibition of Dipeptidyl Peptidase IV Improves Metabolic Control Over a 4-Week Study Period in Type 2 Diabetes

Bo Åhrén, Erik Simonsson, Hillevi Larsson,

Diabetes Care

2002

423

Evidence that oestrogen receptor-α plays an important role in the regulation of glucose homeostasis in mice: insulin sensitivity in the liver

Galyna Bryzgalova, Hui Gao, Bo Åhrén,

Diabetologia

2006

376

Page 1